Work

P2.06-021 Efficacy and Safety of ASP8273 versus Erlotinib or Gefitinib as First-Line Treatment in Subjects with EGFRMut+ NSCLC

Year: 2017

Type: article

Source: Journal of Thoracic Oncology

DOI: 10.1016/j.jtho.2016.11.1514

Authors: Ronan Kelly, Leora Horn, James Chih-Hsin Yang, Dae Ho Lee, Bhardwaj Desai, Tanya Fleege, Fei Jie, Srinivasu Poondru, Anne Keating, Debbie Whitcomb, Tosei Murase, Koichi Uegaki, Kouji Aoyama, Kazuhiko Nakagawa

Institutions: Johns Hopkins University, Johns Hopkins Medicine, Sidney Kimmel Comprehensive Cancer Center, Vanderbilt University, Vanderbilt-Ingram Cancer Center, National Taiwan University Hospital, Asan Medical Center, Astellas Pharma (United States), Astellas Pharma (Japan), Kindai University

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W2568344927

FWCI: 0.226

Cites:

Cited by: 1

Related to: 10